Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 7683 results

  1. KardiaMobile for detecting atrial fibrillation (MTG64)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  2. GaitSmart rehabilitation exercise programme for gait and mobility issues (MTG78)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

  3. Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (MTG40)

    Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.

  4. Curos for preventing infections when using needleless connectors (MTG44)

    Evidence-based recommendations on Curos for preventing infections when using needleless connectors.

  5. ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)

    Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.

  6. Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

      Status ...

  7. The geko device for reducing the risk of venous thromboembolism (MTG19)

    Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.

  8. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

  9. Eszopiclone for treating insomnia TS ID 12020

      Status ...

  10. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040

    Awaiting development [GID-TA11591] Expected publication date: TBC

  11. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064

    Awaiting development [GID-TA11594] Expected publication date: TBC

  12. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042

    Awaiting development [GID-TA11592] Expected publication date: TBC

  13. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036

    Awaiting development [GID-TA11596] Expected publication date: TBC

  14. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]

    In development [GID-TA10930] Expected publication date: 28 May 2025

  15. Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

    In development [GID-TA10620] Expected publication date: TBC